Genta Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of people with cancer. The company has built a broad portfolio of proprietary products in various stages of clinical development. Genta’s drugs in development include Ganite (gallium nitrate), Genasense (oblimersen sodium), Tesetaxel, and oral gallium.
Here is a brief overview of Genta’s four cancer drugs:
• Tesetaxel is a novel, orally-absorbed taxane that is in the same class of drugs as docetaxel and paclitaxel. Tesetaxel has completed several Phase 2 clinical trials. The company has initiated studies of the drug in patients with solid tumors, particularly stomach cancers.
• Genasense injection is a modified DNA-based antisense drug that may enhance the effectiveness of anti-cancer therapy. Enrollment of patients with advanced melanoma in a Phase 3 study is complete.
• Ganite is being currently being marketed by Genta in the United States. It is used for treatment of patients with cancer-related hypercalcemia that is resistant to hydration.
• Oral gallium is in Phase 1 studies for treatment of patients with various conditions associated with bone loss.
For further information on Genta and its drugs in development, please visit its website at www.genta.com.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment